Scholarlink

Background <p>Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by autoantibody production, complement activation, and a chronic relapsing–remitting course. Patients with refractory SLE often have limited treatment options.</p> Methods <p>Three female patients with SLE (median age: 29&#xa0;years) and active disease refractory to immunosuppressive therapies were enrolled in a B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell program. Autologous T cells were transduced with a lentiviral anti-BCMA CAR vector, expanded, and reinfused at a dose of 40&#xa0;M CAR T cells on day 0 and day 2.</p> Results <p>By day 13, clinical improvement and normalization of laboratory parameters were observed in all patients.</p> Conclusions <p>These findings suggest that BCMA CAR-T cell therapy is feasible, tolerable, and exhibits significant efficacy in the short term for the treatment of systemic lupus erythematosus (SLE), supporting further investigation into this therapy.<Table Float="No" ID="Taba"> <tgroup cols="2"> <colspec align="left" colname="c1" colnum="1" /> <colspec align="left" colname="c2" colnum="2" /> <tbody> <row> <entry nameend="c2" namest="c1"> <p><b>Key Points</b></p> <p>•&#xa0;<i>BCMA CAR-T cell therapy was used on three patients with treatment-resistant systemic lupus erythematosus (SLE).</i></p> <p>• <i>The treatment led to rapid improvement in all patients and was found to be feasible, tolerable, and effective.</i></p> </entry> </row> </tbody> </tgroup> </Table></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Application of BCMA CAR-T in systemic lupus erythematosus

  • 期刊论文

  • 发表日期：

    2026年4月20日

查看全文
  • Hailing Liu,
  • Hui Zhang,
  • Yan Xu,
  • Jianli Wang,
  • Wanggang Zhang,
  • Bo Lei

摘要

Background

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by autoantibody production, complement activation, and a chronic relapsing–remitting course. Patients with refractory SLE often have limited treatment options.

Methods

Three female patients with SLE (median age: 29 years) and active disease refractory to immunosuppressive therapies were enrolled in a B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell program. Autologous T cells were transduced with a lentiviral anti-BCMA CAR vector, expanded, and reinfused at a dose of 40 M CAR T cells on day 0 and day 2.

Results

By day 13, clinical improvement and normalization of laboratory parameters were observed in all patients.

Conclusions

These findings suggest that BCMA CAR-T cell therapy is feasible, tolerable, and exhibits significant efficacy in the short term for the treatment of systemic lupus erythematosus (SLE), supporting further investigation into this therapy.

Key Points

• BCMA CAR-T cell therapy was used on three patients with treatment-resistant systemic lupus erythematosus (SLE).

• The treatment led to rapid improvement in all patients and was found to be feasible, tolerable, and effective.